Boston Scientific announces acquisition of Symetis

Boston Scientific has announced the acquisition of the Swiss medical technology company Symetis for $435 million (348.36 million pounds).

The privately-held structural heart company focuses on minimally-invasive transcatheter aortic valve implantation (TAVI) devices, including the Acurate TA and Acurate neo/TF valve systems, for use in the treatment of high-risk patients with severe and symptomatic aortic valve stenosis.

In addition to these devices – which are already sold across Europe – Symetis is developing Acurate neo/AS, a next-generation valve system that is currently being assessed in a clinical trial designed to support a future CE Mark application.

This deal follows Boston Scientific's recent acquisition of certain manufacturing assets of Neovasc and comes as part of the company's continued strategic investment in structural heart solutions.

Dr Ian Meredith, executive vice-president and global chief medical officer of Boston Scientific, said: "The steps we are taking reflect our commitment to being a leader in TAVI and structural heart technologies now and over the long term as we broaden our portfolio and pipeline."

It is expected that the deal will close during the second quarter of 2017.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.